Literature DB >> 32958694

Non-maleficence and the ethics of consent to cancer screening.

Lotte Elton1.   

Abstract

Cancer screening programmes cause harm to individuals via overdiagnosis and overtreatment, even where they confer population-level benefit. Screening thus appears to violate the principle of non-maleficence, since it entails medically unnecessary harm to individuals. Can consent to screening programmes negate the moral significance of this harm? In therapeutic medical contexts, consent is used as a means of rendering medical harm morally permissible. However, in this paper, I argue that it is unclear that the model of consent used within therapeutic medicine can be applied unproblematically to preventive medicine. Invitation to screening changes the pragmatic norms and expectations of the patient-doctor encounter such that two key principles of consent may be violated. First, the pragmatics of a medical invitation are such that patients may fail to be adequately informed, since patients appear to assume medical invitations are made with their best interests in mind, even where information to the contrary is outlined. Second, screening invitations may place pressure on patients; in the context of a medical encounter, to make an invitation to screening may constitute an inducement to accept. In order to be sure that a patient's consent to a screening invitation is valid, we must make clear to patients that their decision to accept screening may be shaped not only by how information about screening is presented, but by the pragmatic form of the invitation itself. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autonomy; clinical ethics; informed consent; public health ethics

Year:  2020        PMID: 32958694      PMCID: PMC8257550          DOI: 10.1136/medethics-2020-106135

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  15 in total

1.  Screening, ethics, and the law.

Authors:  B G Charlton
Journal:  BMJ       Date:  1992-08-29

2.  Imbalance of power between patients and doctors.

Authors:  Christian Koeck
Journal:  BMJ       Date:  2014-12-15

Review 3.  Validation of screening procedures.

Authors:  A L Cochrane; W W Holland
Journal:  Br Med Bull       Date:  1971-01       Impact factor: 4.291

4.  How should we measure informed choice? The case of cancer screening.

Authors:  R G Jepson; J Hewison; A G H Thompson; D Weller
Journal:  J Med Ethics       Date:  2005-04       Impact factor: 2.903

5.  Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial.

Authors:  Jolyn Hersch; Alexandra Barratt; Jesse Jansen; Les Irwig; Kevin McGeechan; Gemma Jacklyn; Hazel Thornton; Haryana Dhillon; Nehmat Houssami; Kirsten McCaffery
Journal:  Lancet       Date:  2015-02-18       Impact factor: 79.321

6.  Power issues in the doctor-patient relationship.

Authors:  F Goodyear-Smith; S Buetow
Journal:  Health Care Anal       Date:  2001

7.  Ethical issues in cancer screening and prevention.

Authors:  Anya Plutynski
Journal:  J Med Philos       Date:  2012-05-07

8.  Why is therapeutic misconception so prevalent?

Authors:  Charles W Lidz; Karen Albert; Paul Appelbaum; Laura B Dunn; Eve Overton; Ekaterina Pivovarova
Journal:  Camb Q Healthc Ethics       Date:  2015-04       Impact factor: 1.566

9.  How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study.

Authors:  R Wuntakal; Alejandra Castanon; R Landy; P Sasieni
Journal:  BMC Pregnancy Childbirth       Date:  2015-09-29       Impact factor: 3.007

10.  Women's views on overdiagnosis in breast cancer screening: a qualitative study.

Authors:  Jolyn Hersch; Jesse Jansen; Alexandra Barratt; Les Irwig; Nehmat Houssami; Kirsten Howard; Haryana Dhillon; Kirsten McCaffery
Journal:  BMJ       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.